 Anne Lynch
Concepts (318)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 13 | 2024 | 142 | 5.870 |
Why?
| | Macular Degeneration | 12 | 2023 | 164 | 3.890 |
Why?
| | Geographic Atrophy | 11 | 2025 | 79 | 3.400 |
Why?
| | Wet Macular Degeneration | 7 | 2025 | 56 | 2.700 |
Why?
| | Birth Weight | 11 | 2024 | 516 | 2.220 |
Why?
| | Complement Factor B | 7 | 2022 | 109 | 2.220 |
Why?
| | Complement Activation | 7 | 2025 | 415 | 2.030 |
Why?
| | Visual Acuity | 17 | 2024 | 356 | 1.860 |
Why?
| | Pre-Eclampsia | 8 | 2024 | 190 | 1.660 |
Why?
| | Neonatal Screening | 5 | 2022 | 169 | 1.660 |
Why?
| | Cataract | 12 | 2024 | 213 | 1.580 |
Why?
| | Retinal Drusen | 3 | 2024 | 31 | 1.570 |
Why?
| | Gestational Age | 16 | 2024 | 910 | 1.550 |
Why?
| | Premature Birth | 5 | 2017 | 333 | 1.410 |
Why?
| | Tomography, Optical Coherence | 8 | 2025 | 213 | 1.180 |
Why?
| | Phacoemulsification | 8 | 2023 | 122 | 1.170 |
Why?
| | Infant, Premature | 7 | 2024 | 574 | 1.080 |
Why?
| | Complement C3a | 2 | 2019 | 42 | 0.990 |
Why?
| | Registries | 9 | 2025 | 2035 | 0.990 |
Why?
| | Cataract Extraction | 7 | 2024 | 98 | 0.910 |
Why?
| | Fluorescein Angiography | 6 | 2025 | 151 | 0.870 |
Why?
| | Infant, Newborn | 16 | 2024 | 6079 | 0.850 |
Why?
| | Diseases in Twins | 1 | 2024 | 169 | 0.850 |
Why?
| | Risk Factors | 23 | 2025 | 10388 | 0.840 |
Why?
| | Retrospective Studies | 38 | 2025 | 15657 | 0.830 |
Why?
| | Diabetic Retinopathy | 5 | 2023 | 189 | 0.820 |
Why?
| | Twins | 1 | 2024 | 243 | 0.820 |
Why?
| | Fetal Membranes, Premature Rupture | 3 | 2017 | 37 | 0.730 |
Why?
| | Pregnancy | 25 | 2024 | 6763 | 0.720 |
Why?
| | Weight Gain | 4 | 2019 | 519 | 0.680 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 135 | 0.650 |
Why?
| | Infant, Low Birth Weight | 2 | 2017 | 141 | 0.640 |
Why?
| | Female | 67 | 2025 | 73304 | 0.630 |
Why?
| | Pregnancy Outcome | 7 | 2015 | 416 | 0.630 |
Why?
| | Humans | 88 | 2025 | 137585 | 0.620 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 39 | 0.620 |
Why?
| | Cohort Studies | 11 | 2024 | 5742 | 0.610 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 56 | 0.590 |
Why?
| | Biomarkers | 11 | 2025 | 4149 | 0.590 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2024 | 383 | 0.580 |
Why?
| | Internet | 1 | 2023 | 655 | 0.580 |
Why?
| | Labor, Induced | 2 | 2017 | 33 | 0.550 |
Why?
| | Algorithms | 6 | 2018 | 1704 | 0.550 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 189 | 0.550 |
Why?
| | Colorado | 12 | 2025 | 4565 | 0.550 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 40 | 0.530 |
Why?
| | Labor, Obstetric | 1 | 2017 | 61 | 0.520 |
Why?
| | Retinal Detachment | 3 | 2023 | 63 | 0.520 |
Why?
| | Blood Proteins | 2 | 2015 | 252 | 0.510 |
Why?
| | Intraocular Pressure | 5 | 2024 | 307 | 0.490 |
Why?
| | Pregnancy Trimester, First | 2 | 2015 | 140 | 0.480 |
Why?
| | Refraction, Ocular | 4 | 2024 | 37 | 0.470 |
Why?
| | Aged, 80 and over | 15 | 2025 | 7635 | 0.460 |
Why?
| | Follow-Up Studies | 13 | 2025 | 5131 | 0.460 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 319 | 0.450 |
Why?
| | Aged | 25 | 2025 | 23961 | 0.450 |
Why?
| | Infant, Very Low Birth Weight | 4 | 2019 | 68 | 0.430 |
Why?
| | Male | 42 | 2025 | 67762 | 0.430 |
Why?
| | Multimodal Imaging | 2 | 2025 | 113 | 0.420 |
Why?
| | Infant | 12 | 2022 | 9465 | 0.420 |
Why?
| | Placenta | 2 | 2018 | 750 | 0.410 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 19 | 0.410 |
Why?
| | Inflammation | 4 | 2023 | 2837 | 0.410 |
Why?
| | Keratomileusis, Laser In Situ | 2 | 2024 | 21 | 0.410 |
Why?
| | Intraoperative Complications | 4 | 2022 | 138 | 0.410 |
Why?
| | Myopia | 3 | 2024 | 47 | 0.400 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2012 | 148 | 0.400 |
Why?
| | Research Design | 1 | 2019 | 1139 | 0.390 |
Why?
| | Cesarean Section | 3 | 2011 | 184 | 0.370 |
Why?
| | Vitrectomy | 3 | 2021 | 70 | 0.370 |
Why?
| | Logistic Models | 9 | 2024 | 2074 | 0.370 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 9 | 0.370 |
Why?
| | Lens Implantation, Intraocular | 4 | 2022 | 59 | 0.360 |
Why?
| | Odds Ratio | 5 | 2019 | 1070 | 0.360 |
Why?
| | Retinal Diseases | 2 | 2023 | 91 | 0.350 |
Why?
| | Body Mass Index | 4 | 2014 | 2389 | 0.350 |
Why?
| | Disease Progression | 6 | 2025 | 2757 | 0.340 |
Why?
| | Pregnancy Complications | 3 | 2010 | 527 | 0.340 |
Why?
| | Complement Activating Enzymes | 1 | 2010 | 3 | 0.330 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2012 | 394 | 0.320 |
Why?
| | Prospective Studies | 15 | 2025 | 7604 | 0.320 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 71 | 0.310 |
Why?
| | Influenza Vaccines | 2 | 2012 | 539 | 0.310 |
Why?
| | Immunologic Factors | 2 | 2022 | 236 | 0.290 |
Why?
| | Influenza, Human | 2 | 2012 | 622 | 0.290 |
Why?
| | Complement Pathway, Alternative | 2 | 2013 | 122 | 0.290 |
Why?
| | Obesity | 3 | 2014 | 2992 | 0.280 |
Why?
| | Antibodies, Antiphospholipid | 3 | 1999 | 25 | 0.280 |
Why?
| | Receptors, Cell Surface | 1 | 2010 | 385 | 0.280 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2019 | 852 | 0.270 |
Why?
| | Lenses, Intraocular | 3 | 2022 | 43 | 0.270 |
Why?
| | Adult | 24 | 2024 | 37929 | 0.270 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 1946 | 0.270 |
Why?
| | Lasers, Excimer | 2 | 2024 | 28 | 0.260 |
Why?
| | Antigens, CD | 1 | 2010 | 521 | 0.260 |
Why?
| | Case-Control Studies | 7 | 2022 | 3556 | 0.240 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 43 | 0.240 |
Why?
| | Time Factors | 5 | 2025 | 6828 | 0.230 |
Why?
| | Incidence | 4 | 2022 | 2804 | 0.230 |
Why?
| | Glaucoma | 2 | 2018 | 237 | 0.230 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2011 | 1329 | 0.220 |
Why?
| | Diabetes Mellitus | 2 | 2023 | 1040 | 0.220 |
Why?
| | Choroid | 1 | 2024 | 62 | 0.210 |
Why?
| | Postoperative Complications | 5 | 2023 | 2654 | 0.210 |
Why?
| | Membrane Proteins | 1 | 2010 | 1164 | 0.200 |
Why?
| | Vitreous Body | 2 | 2022 | 110 | 0.200 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 69 | 0.200 |
Why?
| | Methylprednisolone | 1 | 2023 | 86 | 0.200 |
Why?
| | Optic Neuritis | 1 | 2023 | 41 | 0.200 |
Why?
| | Vision, Low | 1 | 2022 | 16 | 0.200 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 229 | 0.190 |
Why?
| | Vaccination | 1 | 2011 | 1381 | 0.190 |
Why?
| | Middle Aged | 19 | 2025 | 33479 | 0.190 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1509 | 0.190 |
Why?
| | Retinal Perforations | 1 | 2022 | 16 | 0.190 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.180 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.180 |
Why?
| | Proteomics | 2 | 2020 | 1111 | 0.180 |
Why?
| | Capsule Opacification | 1 | 2021 | 22 | 0.180 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.180 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 110 | 0.180 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.180 |
Why?
| | Aberrometry | 1 | 2020 | 9 | 0.170 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.170 |
Why?
| | Complement System Proteins | 2 | 2022 | 327 | 0.170 |
Why?
| | Corneal Transplantation | 1 | 2020 | 13 | 0.170 |
Why?
| | Trabeculectomy | 2 | 2018 | 72 | 0.170 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.170 |
Why?
| | Optics and Photonics | 1 | 2020 | 43 | 0.170 |
Why?
| | Abortion, Spontaneous | 2 | 1999 | 105 | 0.170 |
Why?
| | Risk Assessment | 3 | 2019 | 3457 | 0.170 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 40 | 0.170 |
Why?
| | Strabismus | 1 | 2020 | 29 | 0.170 |
Why?
| | Quality of Life | 5 | 2023 | 2892 | 0.160 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.160 |
Why?
| | Dementia | 1 | 2023 | 259 | 0.160 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2020 | 58 | 0.160 |
Why?
| | Macula Lutea | 1 | 2019 | 21 | 0.160 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 25 | 0.160 |
Why?
| | Laser Therapy | 1 | 2021 | 130 | 0.160 |
Why?
| | Hepatitis C | 1 | 2022 | 271 | 0.160 |
Why?
| | Homosexuality, Male | 1 | 2020 | 184 | 0.160 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 5778 | 0.160 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.150 |
Why?
| | United States | 8 | 2020 | 14841 | 0.150 |
Why?
| | Dermatitis, Atopic | 1 | 2022 | 329 | 0.150 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 146 | 0.150 |
Why?
| | Pilocarpine | 1 | 2018 | 15 | 0.150 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 19 | 0.150 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 1999 | 77 | 0.150 |
Why?
| | Ophthalmic Solutions | 1 | 2018 | 75 | 0.140 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 17 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2531 | 0.140 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 79 | 0.140 |
Why?
| | Ocular Hypertension | 1 | 2018 | 69 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 331 | 0.140 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 496 | 0.140 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 17 | 0.130 |
Why?
| | Glycoproteins | 1 | 1999 | 342 | 0.130 |
Why?
| | Parity | 1 | 2017 | 126 | 0.130 |
Why?
| | Laser Coagulation | 1 | 2017 | 68 | 0.130 |
Why?
| | Glaucoma, Open-Angle | 1 | 2018 | 103 | 0.130 |
Why?
| | Automobile Driving | 1 | 2018 | 148 | 0.130 |
Why?
| | Tonometry, Ocular | 3 | 2024 | 97 | 0.130 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 20 | 0.130 |
Why?
| | Fetus | 2 | 2018 | 806 | 0.120 |
Why?
| | Recovery of Function | 1 | 2019 | 653 | 0.120 |
Why?
| | Risk | 1 | 2018 | 912 | 0.120 |
Why?
| | Young Adult | 8 | 2019 | 13209 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2828 | 0.120 |
Why?
| | Time-to-Pregnancy | 1 | 2015 | 5 | 0.120 |
Why?
| | Fundus Oculi | 2 | 2025 | 65 | 0.110 |
Why?
| | Cross-Sectional Studies | 5 | 2024 | 5472 | 0.110 |
Why?
| | Mothers | 2 | 2018 | 754 | 0.110 |
Why?
| | Phenotype | 2 | 2022 | 3196 | 0.110 |
Why?
| | Proteins | 1 | 2020 | 1009 | 0.110 |
Why?
| | Self Report | 1 | 2018 | 827 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 257 | 0.110 |
Why?
| | Obstetric Labor, Premature | 1 | 2013 | 36 | 0.110 |
Why?
| | Cervical Ripening | 1 | 2013 | 9 | 0.100 |
Why?
| | Cervix Uteri | 1 | 2013 | 48 | 0.100 |
Why?
| | Sulfonamides | 1 | 2016 | 513 | 0.100 |
Why?
| | Uterine Hemorrhage | 1 | 2013 | 37 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2024 | 10811 | 0.090 |
Why?
| | Pulmonary Fibrosis | 2 | 2008 | 402 | 0.090 |
Why?
| | Models, Statistical | 1 | 2016 | 669 | 0.090 |
Why?
| | Aspirin | 1 | 2015 | 387 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 15 | 0.090 |
Why?
| | Tertiary Healthcare | 2 | 2022 | 33 | 0.090 |
Why?
| | Infant, Small for Gestational Age | 1 | 2012 | 92 | 0.090 |
Why?
| | Fetal Blood | 1 | 2013 | 327 | 0.090 |
Why?
| | Autoantibodies | 1 | 1999 | 1496 | 0.090 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2015 | 463 | 0.090 |
Why?
| | Endoglin | 1 | 2010 | 19 | 0.080 |
Why?
| | Adiposity | 1 | 2014 | 518 | 0.080 |
Why?
| | Hypertension | 1 | 1999 | 1295 | 0.080 |
Why?
| | Cesarean Section, Repeat | 1 | 2009 | 11 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 545 | 0.080 |
Why?
| | Intensive Care, Neonatal | 1 | 2009 | 40 | 0.080 |
Why?
| | Postoperative Period | 2 | 2020 | 342 | 0.080 |
Why?
| | Placental Insufficiency | 1 | 2010 | 116 | 0.080 |
Why?
| | Child | 4 | 2022 | 21935 | 0.070 |
Why?
| | Models, Biological | 1 | 2016 | 1783 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2022 | 512 | 0.070 |
Why?
| | Seasons | 1 | 2011 | 547 | 0.070 |
Why?
| | Pregnancy Trimester, Third | 1 | 2008 | 114 | 0.070 |
Why?
| | Heart Rate | 1 | 2012 | 822 | 0.070 |
Why?
| | Elective Surgical Procedures | 1 | 2009 | 179 | 0.070 |
Why?
| | Health Status Disparities | 1 | 2011 | 289 | 0.070 |
Why?
| | ROC Curve | 2 | 2019 | 554 | 0.070 |
Why?
| | Resuscitation | 1 | 2009 | 251 | 0.070 |
Why?
| | Patient Compliance | 1 | 2011 | 581 | 0.060 |
Why?
| | Glyburide | 1 | 2006 | 32 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3715 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 2031 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2008 | 2691 | 0.060 |
Why?
| | Ultrasonography, Doppler | 1 | 2005 | 124 | 0.060 |
Why?
| | Blood Pressure | 1 | 2012 | 1786 | 0.060 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1291 | 0.060 |
Why?
| | Papanicolaou Test | 1 | 2004 | 43 | 0.060 |
Why?
| | Urban Health | 1 | 2004 | 92 | 0.060 |
Why?
| | Vaginal Smears | 1 | 2004 | 57 | 0.060 |
Why?
| | Fetal Growth Retardation | 2 | 2012 | 565 | 0.060 |
Why?
| | Refractive Errors | 1 | 2024 | 18 | 0.050 |
Why?
| | Contraceptives, Oral, Combined | 1 | 2004 | 19 | 0.050 |
Why?
| | Uterus | 1 | 2005 | 215 | 0.050 |
Why?
| | Prevalence | 2 | 2024 | 2734 | 0.050 |
Why?
| | Hospitals, County | 1 | 2023 | 11 | 0.050 |
Why?
| | Ovarian Follicle | 1 | 2004 | 72 | 0.050 |
Why?
| | Retinal Pigment Epithelium | 1 | 2024 | 77 | 0.050 |
Why?
| | Length of Stay | 1 | 2009 | 1215 | 0.050 |
Why?
| | Double-Blind Method | 4 | 2015 | 1993 | 0.050 |
Why?
| | Neuroprotection | 1 | 2023 | 42 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2011 | 1587 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 143 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 216 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 34 | 0.050 |
Why?
| | Pandemics | 1 | 2011 | 1639 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 157 | 0.050 |
Why?
| | Diabetes, Gestational | 1 | 2006 | 318 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 114 | 0.050 |
Why?
| | Cornea | 1 | 2022 | 138 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 168 | 0.040 |
Why?
| | Vision Disorders | 1 | 2022 | 142 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 59 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 56 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 261 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 21 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 13 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2020 | 56 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 67 | 0.040 |
Why?
| | Growth Charts | 1 | 2019 | 14 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 93 | 0.040 |
Why?
| | HIV | 1 | 2020 | 234 | 0.040 |
Why?
| | beta 2-Glycoprotein I | 1 | 1999 | 6 | 0.040 |
Why?
| | Canada | 1 | 2020 | 418 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 40 | 0.040 |
Why?
| | Adolescent | 5 | 2020 | 21513 | 0.040 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1999 | 11 | 0.040 |
Why?
| | Pulmonary Gas Exchange | 1 | 1999 | 121 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 213 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 314 | 0.040 |
Why?
| | Positive-Pressure Respiration | 1 | 1999 | 80 | 0.040 |
Why?
| | Phosphatidylserines | 1 | 1999 | 91 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 15 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 12 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2004 | 806 | 0.040 |
Why?
| | Confidence Intervals | 1 | 1999 | 329 | 0.040 |
Why?
| | Family | 1 | 2022 | 671 | 0.040 |
Why?
| | Child, Preschool | 3 | 2022 | 11074 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2844 | 0.030 |
Why?
| | Physical Examination | 1 | 2019 | 241 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 1999 | 289 | 0.030 |
Why?
| | Bronchodilator Agents | 1 | 1999 | 252 | 0.030 |
Why?
| | North America | 1 | 2018 | 313 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 786 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 762 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 522 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 971 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 726 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1999 | 318 | 0.030 |
Why?
| | Interferon-beta | 2 | 2008 | 92 | 0.030 |
Why?
| | Plethysmography | 1 | 2014 | 106 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 1999 | 893 | 0.030 |
Why?
| | Apgar Score | 1 | 1994 | 17 | 0.030 |
Why?
| | Nitric Oxide | 1 | 1999 | 915 | 0.030 |
Why?
| | Respiratory Function Tests | 2 | 2008 | 600 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1996 | 0.030 |
Why?
| | Mice | 1 | 2010 | 17787 | 0.020 |
Why?
| | Linear Models | 1 | 2014 | 849 | 0.020 |
Why?
| | Treatment Failure | 2 | 2006 | 356 | 0.020 |
Why?
| | Organ Size | 1 | 2013 | 477 | 0.020 |
Why?
| | Maternal-Fetal Exchange | 1 | 2012 | 165 | 0.020 |
Why?
| | Body Composition | 1 | 2014 | 684 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2014 | 635 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1289 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2012 | 625 | 0.020 |
Why?
| | Animals | 1 | 2010 | 36940 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 530 | 0.020 |
Why?
| | Fetal Macrosomia | 1 | 2006 | 62 | 0.020 |
Why?
| | Rheology | 1 | 2005 | 92 | 0.010 |
Why?
| | Chicago | 1 | 2004 | 61 | 0.010 |
Why?
| | Survival Analysis | 1 | 2008 | 1325 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2008 | 1266 | 0.010 |
Why?
| | Ethinyl Estradiol | 1 | 2004 | 16 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2004 | 38 | 0.010 |
Why?
| | Desogestrel | 1 | 2004 | 46 | 0.010 |
Why?
| | Ultrasonography, Prenatal | 1 | 2005 | 285 | 0.010 |
Why?
| | Menstrual Cycle | 1 | 2004 | 133 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2004 | 786 | 0.010 |
Why?
| | Women's Health | 1 | 2004 | 372 | 0.010 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 257 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 1024 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1999 | 688 | 0.010 |
Why?
| | Oxygen | 1 | 1999 | 931 | 0.010 |
Why?
| | Hypoxia | 1 | 1999 | 1112 | 0.010 |
Why?
|
|
Lynch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|